Therapy of elderly/comorbid patients with chronic lymphocytic leukemia

Current Pharmaceutical Design

Volumn 18, Issue 23, 2012, Pages 3399-3405

  Smolej, Lukáš ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Chronic lymphocytic leukemia; Comorbidity; Comprehensive geriatric assessment; Creatinine clearance; Elderly patients; Health related quality of life; Low dose fludarabine

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIRUBICIN; FLUDARABINE; METHYLPREDNISOLONE; OFATUMUMAB; RITUXIMAB;

ARTICLE; BACTERIAL INFECTION; BONE MARROW TOXICITY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; COMORBIDITY; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

AGED; COMORBIDITY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NEOPLASM STAGING; RECURRENCE;

EID: 84863529240     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212801227096     Document Type: Article

References (63)

1. Dores GM, Anderson WF, Curtis RE, et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol 2007; 139(5): 809-19.
2. Linet MS, Schubauer-Berigan MK, Weisenburger DD, et al. Chronic lymphocytic leukaemia: an overview of aetiology in light of recent developments in classification and pathogenesis. Br J Haematol 2007; 139(5): 672-86.
3. National Cancer Institute: SEER Cancer Statistics Review. Available at http: //seer. cancer.gov. Accessed on 10.2.2010
4. Hallek M., Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-74.
5. Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010; 28(10): 1756-65
6. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370(9583): 230-9.
7. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107(3): 885-91.
8. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007; 25(7): 793-8.
9. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27(26): 4378-84.
10. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343(24): 1750-7.
11. Robak T, Jamroziak K, Gora-Tybor J, et al. Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol 2010; 28(11): 1863-9.
12. Diehl LF, Karnell LH, Menck HR. The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer 1999; 86(12): 2684-92.
13. Thurmes P, Call T, Slager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma 2008; 49(1): 49-56.
14. Wierda WG, O'Brien S, Wang X, et al. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol 2009; 27(10): 1637-43.
15. Abrisqueta P, Pereira A, Rozman C, et al. Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience. Blood 2009; 114(10): 2044-50
16. Eichhorst B, Goede V, Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009; 50(2): 171-8.
17. Lindeman RD. Changes in renal function with aging. Implications for treatment. Drugs Aging 1992; 2(5): 423-31.
18. Plunkett W, Gandhi V, Huang P, et al. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol 1993; 20(5 Suppl 7): 2-12.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 31-41.
20. Martell RE, Peterson BL, Cohen HJ, et al. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. Cancer Chemother Pharmacol 2002; 50(1): 37-45.
21. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291: 2441-7.
22. Janssen-Heijnen ML, van Spronsen DJ, Lemmens VE, et al. A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International prognostic index. Br J Haematol 2005; 129: 597-606.
23. Cramer P, Goede V, Jenke P, et al. Impact of different chemotherapy regimen in comorbid patients with advanced chronic lymphocytic leukemia: metaanalysis of two phase-III-trials of the German CLL study group. Blood 2006; 108 (abstract 2840)
24. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111(12): 5446-56.
25. Muntanola A, Bosch F, Arguis P, et al. Abdominal computed tomography predicts progression in patients with Rai stage 0 chronic lymphocytic leukemia. J Clin Oncol 2007; 25(12): 1576-80.
26. Norin S, Kimby E, Lundin J. Tumor burden status evaluated by computed tomography scan is of prognostic importance in patients with chronic lymphocytic leukemia. Med Oncol 2009; 27(3): 820-5.
27. Eichhorst BF, Fischer K, Fink AM, et al. Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. Blood 2011; 117(6): 1817-21.
28. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007; 25(14): 1824-31.
29. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 1968; 16(5): 622-6.
30. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998; 16: 1582-7.
31. Molica S. Quality of life in chronic lymphocytic leukemia: a neglected issue. Leuk Lymphoma 2005; 46: 1709-14.
32. Else M, Smith AG, Cocks K, et al. Patients' experience of chronic lymphocytic leukaemia: baseline health-related quality of life results from the LRF CLL4 trial. Br J Haematol 2008; 143: 690-7.
33. Eichhorst BF, Busch R, Obwandner T, et al., Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group. J Clin Oncol 2007; 25: 1722-31.
34. Altman SJ, Haut A, Cartwright GE, Wintrobe MM. Early experience with p-(N,N-di-2- chloroethyl)-aminophenylbutyric acid (CB 1348), a new chemotherapeutic agent effective in the treatment of chronic lymphocytic leukemia. Cancer 1956; 9(3): 512-7.
35. Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009; 114(16): 3382-91.
36. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http: //ctep.cancer. gov/ protocolDevelopment/electronic_ applications/ docs/ctcaev3.pdf. Accessed on 19/09/2011
37. Ferrajoli A, O'Brien S, Wierda W, et al. Treatment of patients with CLL 70 years old and older: a single center experience of 142 patients. Leuk Lymphoma 2005; 46: (Suppl 1): S86 (abstract P95).
38. Shvidel L, Shtalrid M, Bairey O, et al; Israeli Study Group on CLL. Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia. Leuk Lymphoma 2003; 44(11): 1947-50.
39. Bocchia M, Bigazzi C, Marconcini S, et al. Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas. Haematologica 1999; 84(8): 716-20.
40. Fabbri A, Lenoci M, Gozzetti A, et al. Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. Hematol J 2004; 5(6): 472-4.
41. Fabbri A, Lenoci M, Gozzetti A, et al. Low-dose oral fludarabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma. Br J Haematol 2007; 139(1): 90-3.
42. Forconi F, Fabbri A, Lenoci M, et al. Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia. Hematol Oncol 2008; 26(4): 247-51.
43. Marotta G, Bigazzi C, Lenoci M, Tozzi M, Bocchia M, Lauria F. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy. Haematologica 2000; 85(12): 1268-70
44. Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27(4): 498-503.
45. Smolej L, Brychtová Y, Špaček M, et al. Low-dose fludarabine and cyclophosphamide combined with rituximab is a safe and effective treatment option for elderly/comorbid patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): preliminary results of project Q-lite by Czech CLL Study Group. 14th International Workshop in CLL. Clin Lymphoma Myeloma Leukemia 2011; 11 (Suppl 2): S2561 (abstract 5.27)
46. Mulligan SP, Gill D, Turner P, et al. Safety and Tolerability of Oral Fludarabine, with or without Oral Cyclophosphamide and Intravenous Rituximab Therapy, in Previously Untreated Patients with Chronic Lymphocytic Leukaemia Aged 65 Years or Older: Second Interim Analysis from the Australasian Leukaemia and Lymphoma Group and CLL Australian Research Consortium CLL5 Study. International Workshop in CLL. Clin Lymphoma Myeloma Leukemia 2011; 11 (Suppl 2): S259-60 (abstract 5.25)
47. National Cancer Institute: Registry of clinical trials. Cited on 20/09/2011. Available at http: // http: //www.cancer.gov/ clinicaltrials/ search.
48. Shanafelt TD, Lin T, Geyer SM, et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 2007; 109: 2291-8.
49. Smolej L. Modern concepts in the treatment of chronic lymphocytic leukemia. Hematology 2009; 14: 249-54.
50. Gribben JG, Hallek M. Rediscovering alemtuzumab: current and emerging therapeutic roles. Br J Haematol 2009; 144(6): 818-31.
51. Tam CS, O'Brien S, Lerner S, et al. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma 2007; 48(10): 1931-9.
52. Dungarwalla M, Evans SO, Riley U, et al. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica 2008; 93(3): 475-6.
53. Bowen DA, Call TG, Jenkins GD, et al. Methylprednisolonerituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007; 48(12): 2412-7
54. Castro JE, Sandoval-Sus JD, Bole J, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008; 22(11): 2048-53.
55. Quinn J, Sajir M, Chipperfield K, et al. Efficacy of rituximab in combination with steroids in refractory chronic lymphocytic leukaemia. Leuk Lymphoma 2008; 49: 1995-1998
56. Doubek M, Smolej L, Panovska A, Brychtova Y, Mayer J. Rituximab in combination with dexamethasone or high-dose methylprednisolone in refractory chronic lymphocytic leukemia. XIII International Workshop on Chronic Lymphocytic Leukemia; Spain, 16-18 October 2009. Haematologica 2009; 94(s3): abstract 7.3
57. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab As Single- Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia. J Clin Oncol 2010; 28: 1749-55.
58. Hillmen P, Gribben JG, Follows GA, et al. Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open- Label Phase II Study. Blood (ASH Annual Meeting Abstracts), 2010; 116: abstract 697.
59. Foà R, Ciolli S, Di Raimondo F, et al. A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis. Blood (ASH Annual Meeting Abstracts) 2010; 116: abstract 2462
60. Bologna L, Gotti E, Manganini M, et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011; 186(6): 3762-9
61. Goede V, Fischer K, Busch R, et al. Chemoimmunotherapy with Chlorambucil and the Type II CD20-Antibody GA101 In Patients with Chronic Lymphocytic Leukemia and Comorbidity: Results of the Run-In Phase of the CLL11 (BO21004) Trial. Blood (ASH Annual Meeting Abstracts) 2010; 116: abstract 1387
62. Fischer K, Cramer P, Busch R, et al. Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011; 29(26): 3559-66.
63. Badoux XC, Keating MJ, Wen S, et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 2011; 118(13): 3489-981.